Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy

BACKGROUND: Modified albumin-bilirubin (mALBI) grade has been established as a survival determinant in hepatocellular carcinoma (HCC) patients who receive locoregional and targeted therapies. AIM: To investigate whether mALBI could predict survival in unresectable HCC (uHCC) patients who were treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Navadurong, Huttakan, Prasoppokakorn, Thaninee, Siriwong, Nanicha, Phathong, Chonlada, Teeyapun, Nattaya, Tanasanvimon, Suebpong, Thanapirom, Kessarin, Komolmit, Piyawat, Tangkijvanich, Pisit, Treeprasertsuk, Sombat, Chaiteerakij, Roongruedee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Retrospective Cohort Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631433/
https://www.ncbi.nlm.nih.gov/pubmed/37969413
http://dx.doi.org/10.4251/wjgo.v15.i10.1771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631433/
https://www.ncbi.nlm.nih.gov/pubmed/37969413
http://dx.doi.org/10.4251/wjgo.v15.i10.1771

Ejemplares similares